Survival Benefits of Smoking Cessation After Breast Cancer Diagnosis
Author(s) -
Michael N. Passarelli,
Polly A. Newcomb
Publication year - 2017
Publication title -
jnci cancer spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.345
H-Index - 10
ISSN - 2515-5091
DOI - 10.1093/jncics/pkx005
Subject(s) - medicine , smoking cessation , breast cancer , oncology , medline , cancer , pathology , political science , law
We now recognize that cigarette smokers have about a 10% increased risk of developing breast cancer over never smokers, albeit far from the 600% to 800%, or more, increased risk for cancers of organs in direct contact with carcinogens in smoke such as lung, head and neck, bladder, and others (1). For established smoking-related malignancies, continued smoking after diagnosis is associated with increased risk of disease progression and death (2), but much less is known about postdiagnosis smoking and outcomes for cancers, such as breast, for which smoking is not a particularly strong risk factor. Postdiagnosis assessments of smoking habits are frequently missed, both in the clinic (3) and as part of follow-up in longitudinal research studies (4), making it a challenge to estimate any association with change in smoking behavior. Many breast cancer patients who smoke at the time of their diagnosis deny that the habit was a cause of their own cancer, but about 60% of these women acknowledge that smoking may be a cause of breast cancer for some women (5). Regardless of their beliefs on the causes of their own malignancy, it is unclear whether a similar proportion would deny that continuing to smoke is a cause of complications and earlier death from metastatic breast cancer, given that nearly all oncology care providers agree that smoking impacts outcomes (3). About onethird of women with breast cancer who smoke successfully quit within two years following diagnosis (6). This exceeds the proportion of cancer-free women who quit during the same period (6), but still falls short of quit rates reported for patients with lung and head and neck cancers (7). The accompanying article by Parada et al. (8) describes an analysis from the Long Island Breast Cancer Study Project (LIBCSP), which followed 1508 women with breast cancer recruited from Nassau and Suffolk counties in New York between 1996 and 1997, and measured smoking at diagnosis and again an average of 5.5 years after diagnosis. Consistent with age-standardized smoking prevalence estimates for American women at the time (9), the overall prevalence of current smoking at diagnosis in LIBSCP was about 19%, with about half of those at-diagnosis smokers reporting they had quit after diagnosis (8% of the total were still smoking at the follow-up assessment). The study found that continuing to smoke after breast cancer results in poorer overall survival relative to women who quit upon receiving their diagnosis. The increased risk of death from any cause for continued smokers should not come as a surprise given the litany of recognized adverse outcomes of smoking, including increased risk of wound infections from mastectomy and breast conserving surgery (10), respiratory and cardiovascular comorbidities (11), second primary malignancies (12), and poorer overall quality of life (13). A diseasespecific association, on the other hand, may be indicative of more direct effects on tumor burden, including potentially poorer response to endocrine therapy (14) or subsequent contralateral breast cancer (15). Parada et al. estimated an adjusted hazard ratio (HR) for breast cancer–specific survival comparing women who continued to smoke after diagnosis with never smokers of 1.60 (95% confidence interval [CI] 1⁄4 0.79 to 3.23). Although imprecise because only 125 of 426 (29%) total deaths were from breast cancer, the magnitude of this association is very similar to that previously reported by the Collaborative Women’s Longevity Study (CWLS) (16). A fixed-effect meta-analysis of LIBCSP and CWLS would put this HR estimate at 1.69 (95% CI1⁄4 1.18 to 2.41), without exclusion of women with in situ carcinoma from LIBCSP. Also consistent between the two studies is the association for breast cancer–specific survival comparing women who quit at the time of diagnosis with never smokers, similarly combined as 1.10 (95% CI1⁄4 0.73 to 1.64). Dividing these estimates suggests approximately one-third lower risk of death from breast cancer for women who quit upon receiving news of their
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom